So I have been in AMBS for nearly a year now. Been preoccupied recently and haven't had as much time for DD as I would like. Basically, are we waiting till 7/31 now in order to hear the sensitivity and specificity numbers?

Am I missing something or how is this correlated to a concussion conference? Concussion > brain damage > increased risk for AD, oh and by the way look at these numbers we received in our latest test?? I feel like not as many eyes will be on the C4CT that were focused on Copenhagen. Drawing out the numbers makes me a little nervous.

Also, if the numbers are good, isn't this the feasible course: increased pps, probable dip until partnership announced (hopefully including funding), followed by a rather large increase in pps (fingers crossed)? My fear is what happens after. Stall zone until _______ ? Just trying to make sense of what is going on here. AMBS seems to have a lot of irons in the fire, and I have been out of the loop for a while.

I guess I am hoping to see this thing get uplisted before MANF gets even more promising (again, fingers crossed) followed by a buyout…wishful thinking?